Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
RegulatoryapprovedIsembyldPositive
AI Analysis
Summary
Scholar Rock obtained FDA approval for Isembyld, its spinal muscular atrophy drug, following an initial rejection in September 2025 that cited third-party manufacturer compliance issues.
Outcome Details
FDA approval secured after previous rejection in September 2025 due to third-party manufacturer compliance issues
Importance:8/10
Sentiment:
0.75
FDA approvalrare diseasespinal muscular atrophyregulatorymuscle-targeting
Related Companies
Read the original article
Published by BioSpace on September 14, 2026 12:17 PM